Pipeline
ABUIABACGAAgjtGN4QUo6L_E5AYw6Ac44AM

The company has yield notable achievements in R&D. For more than a decade, the company has remained committed to the combination of Chinese and Western technologies, and has paid closer attention to the fields of digestive system, the neuropsychiatric system and the otolaryngology. The company is now expanding its pipeline into fields as varied as cardio-cerebral vascular diseases,metabolic chronic diseases, immunology and oncology. Since its establishment, the company which started with one health care product approval has gradually obtained the first generic drug approvals  such as Weidimei( Hydrotalcite Tablets /Chewabletablets), Changsong (Macrogol 4000Powder), Gabexate Mesylate for Injection and unique Chinese patent medicines like Duliang Soft Capsules, Tongxiening Granules,Ganjuebingmei Tablets, Liuweianshen Capsules, and Baweiqilong Granules. Currently, it has 68 drugs approvals, including 49 drugs in the national "medical insurance" catalog, 46 drugs with domestic patents and one with the international patent.The R&D and project application team of the company has successively undertaken the high-tech industrialization project of the national development and reform commission, the "Twelfth Five-Year Plan" major new drug innovation projects of the Ministry of Science and Technology, and research projects of the State Administration of TCM of the TCM industry and nearly 100 scientific research projects of Chongqing Municipality.The company obtained two " National Patent Award" and one "Third Prize of National Prize for Progress in Science and Technology".